Cardiff Oncology, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cardiff Oncology, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $366.0K | Feb 25, 2021 |
| FY2020 | Dec 31, 2019 | $244.6K | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $378.3K | Feb 27, 2020 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $593.0K | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $683.0K | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $488.0K | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $386.0K | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $359.0K | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $366.0K | Feb 24, 2022 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $378.3K | Mar 6, 2019 |
| FY2017 | Dec 31, 2017 | $185.0K | Feb 26, 2018 |
| FY2017 | Sep 30, 2017 | $123.0K | Feb 26, 2018 |
| FY2017 | Jun 30, 2017 | $102.0K | Feb 26, 2018 |
| FY2017 | Mar 31, 2017 | $95.0K | Feb 26, 2018 |
| FY2017 | Dec 31, 2016 | $68.0K | Feb 26, 2018 |
| FY2017 | Sep 30, 2016 | $89.0K | Feb 26, 2018 |
| FY2017 | Jun 30, 2016 | $104.0K | Feb 26, 2018 |
| FY2017 | Mar 31, 2016 | $120.0K | Feb 26, 2018 |
| FY2016 | Dec 31, 2015 | $79.0K | Mar 15, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($45.85M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($45.43M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($41.44M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($38.70M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($28.29M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($19.31M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($16.41M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($16.46M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($24.91M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($39.20M) | Feb 26, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($48.96M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($48.65M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($45.41M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($39.90M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($28.86M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($19.09M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($16.68M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($17.05M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($25.60M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($40.15M) | Feb 26, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $27.10M | Mar 2, 2023 |
| FY2021 | Dec 31, 2021 | $17.40M | Feb 24, 2022 |
| FY2020 | Dec 31, 2020 | $11.24M | Feb 25, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.22M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $12.48M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $13.04M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $13.18M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $11.84M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $8.22M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $5.76M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $8.01M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $14.23M | Mar 6, 2019 |
| FY2013 | Dec 31, 2013 | $7.00M | Mar 17, 2014 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($37.92M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($37.69M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($30.89M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($33.82M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($23.04M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($16.32M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($13.27M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($13.20M) | Feb 27, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.0K | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $80.0K | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $582.0K | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $1.01M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $205.0K | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $211.0K | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $67.6K | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $5.1K | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $101.1K | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $823.5K | Feb 26, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.88M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $97.19M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $81.64M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $116.19M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $149.54M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $134.73M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $13.09M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $14.17M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $12.28M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $43.95M | Feb 26, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.50M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $14.24M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $11.90M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $9.85M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $9.13M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $6.57M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $5.78M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $4.09M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $5.78M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $24.18M | Feb 26, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.39M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $82.95M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $69.74M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $106.34M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $140.42M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $128.16M | Mar 2, 2023 |
| FY2021 | Dec 31, 2019 | $7.31M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $10.08M | Feb 25, 2021 |
| FY2019 | Dec 31, 2017 | $6.51M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $19.77M | Mar 6, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($430.03M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($384.18M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($339.54M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($298.10M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($259.81M) | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | ($231.50M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($208.90M) | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | ($192.19M) | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | ($173.05M) | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | ($148.12M) | Feb 26, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.47M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $51.47M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $21.66M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $16.35M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $11.94M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | $130.98M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $10.20M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | $11.45M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $8.23M | Mar 6, 2019 |
| FY2018 | Dec 31, 2016 | $13.92M | Mar 6, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Feb 24, 2022 |
| FY2018 | Dec 31, 2018 | (8) | Mar 6, 2019 |
| FY2017 | Dec 31, 2017 | 0 | Feb 26, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Feb 26, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Feb 26, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Feb 24, 2022 |
| FY2018 | Dec 31, 2018 | (8) | Mar 6, 2019 |
| FY2017 | Dec 31, 2017 | 0 | Feb 26, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Feb 26, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Feb 26, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 68.31M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 66.52M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 44.68M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 44.68M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 41.96M | Mar 2, 2023 |
| FY2021 | Dec 31, 2020 | 36.78M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 8.59M | Feb 25, 2021 |
| FY2019 | Dec 31, 2018 | 3.83M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 733,217 | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | 30.70M | Feb 26, 2018 |